Swedbank AB Buys 5,032 Shares of Stryker Co. (NYSE:SYK)

Swedbank AB boosted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 51,070 shares of the medical technology company's stock after purchasing an additional 5,032 shares during the period. Swedbank AB's holdings in Stryker were worth $18,450,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SYK. Centennial Bank AR boosted its stake in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $36,000. HBW Advisory Services LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Hara Capital LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $42,000. Finally, Grove Bank & Trust boosted its stake in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock worth $44,000 after acquiring an additional 56 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 7,347 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company's stock, valued at approximately $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,781 shares of company stock valued at $24,612,275 in the last 90 days. Corporate insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Evercore ISI lifted their target price on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Royal Bank of Canada boosted their price target on Stryker from $386.00 to $400.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Finally, Needham & Company LLC boosted their price target on Stryker from $393.00 to $409.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $393.65.

Stryker Price Performance

Stryker stock opened at $389.71 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 52 week low of $285.79 and a 52 week high of $398.20. The stock has a market capitalization of $148.57 billion, a P/E ratio of 41.77, a price-to-earnings-growth ratio of 2.90 and a beta of 0.91. The stock has a fifty day moving average of $366.97 and a 200-day moving average of $350.42.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, sell-side analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.